La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Talkspace a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Talkspace..

Talkspace (NASDAQ:TALK) Azioni, Catena delle Opzioni

Talkspace

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue primarily stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

Talkspace Inc

Susquehanna analyst Joseph Stauff maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Positive and lowers the price target from $56 to $54.

News

Price Target

Analyst Ratings

DKNG

Susquehanna Maintains Positive on DraftKings, Lowers Price Target to $54

<a href="https://news.gm.com/home.detail.html/Pages/topic/us/en/2025/jan/0108-ai-ev.html" title="https://news.gm.com/home.detail.html/Pages/topic/us/en/2025/jan/0108-ai-ev.html">https://news.gm.com/home.detail.html/Pages/topic/us/en/2025/jan/0108-ai-ev.html</a>

EVGO

GM Collaborating With EVgo To Build Total Of 2,850 DC Public Charging Stalls Across U.S.; Teamed Up With Pilot Travel Centers & EVgo To Add Up To 2,000 DC Fast Charging Stalls At Up To 500 Pilot & Flying J Travel Centers Across U.S.

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $142 to $162.

NBIX

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $162

Macro Economic Events

Econ #s

Economics

USA Wholesale Inventories (MoM) For November -0.2% Vs -0.2% Est.; -0.2% Prior

Kevin O&#8217;Leary, the outspoken investor and business owner, has some strong words for President Joe Biden. O&#8217;Leary called <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">Biden&#8217;s decision to block</a> the almost $15 billion sale of U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) to Japan&#8217;s Nippon Steel (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) a &#8220;mistake&#8221; and accused the government of &#8220;picking winners and losers, one specific company over another.&#8221;
The proposed deal, which had been in the works for over a year, involved Nippon Steel making significant investments in U.S. Steel to modernize its operations and ensure its survival amid tough foreign competition. But Biden stopped the deal because he was worried it could hurt U.S. security. This decision has led to many arguments.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is a mistake and sends a bad message. You want to make America the number one destination for capital all around the world. You want everyone to bring their dollars, build plants and equipment in the United States because it&#39;s the most competitive and largest economy. You do… <a href="https://t.co/hGy3QFWorx">pic.twitter.com/hGy3QFWorx</a>
&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1875333184210055394?ref_src=twsrc%5Etfw">January 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
O&#8217;Leary was direct in his criticism. &#8220;You want to make America the number one destination for capital all around the world,&#8221; he said during a recent Fox Business <a href="https://www.youtube.com/watch?v=SsvbFP1PquA">interview</a>. &#8220;You want them to bring their dollars and build plants and equipment in the United States because it's the most competitive and largest economy. You do not want to mess with that.&#8221;
Biden, on the other hand, stated that keeping U.S. Steel domestically owned is essential for national security and resilient supply chains: &#8220;Steel production – and the steelworkers who produce it – are the backbone of our nation.&#8221;
However, O&#8217;Leary argued that Nippon Steel had already pledged to invest up to $15 billion to upgrade U.S. Steel&#8217;s plants, create jobs and ensure steel production met American standards. This is exactly what you want, O&#8217;Leary said. &#8220;The number one export of the United States isn't steel, <a href="https://www.benzinga.com/personal-finance/24/09/40692513/theres-a-reason-people-go-through-barbed-wire-to-get-here-says-kevin-oleary-we-cant-afford-polic">it's the American dream</a>. You should always want your money here first.&#8221;
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
After Biden's decision, U.S. Steel's <a href="https://www.benzinga.com/markets/25/01/42780788/us-steel-tumbles-nearly-10-in-overnight-trading-on-robinhood-as-biden-reportedly-plans-to-block-149b-nippon-steel-merger">stock value dropped</a>. The company and Nippon Steel released a joint statement saying the decision was unfair and against the law. U.S. Steel's CEO, David Burritt, went further, calling the move "shameful and corrupt." He said Biden's actions insulted Japan, a close ally and gave an advantage to competitors in China.
Meanwhile, supporters of Biden's move, including the powerful United Steelworkers union, celebrated it, saying, &#8220;We're grateful for President Biden's willingness to take bold action to maintain a strong domestic steel industry.&#8221; Pennsylvania's Gov. Josh Shapiro also praised the decision and urged U.S. Steel to focus on keeping jobs in the state.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Critics worry that blocking the deal could have bigger consequences. Nippon Steel had promised to keep U.S. Steel's headquarters in Pittsburgh, ensure Americans stayed in charge and prioritize steel production for U.S. needs. They said the deal would have helped U.S. Steel compete against cheaper steel from countries like China.
O&#8217;Leary remains adamant that the move hurts America's reputation as a destination for global investment. "This is counterproductive," he said. &#8220;I hope that actually Trump overturns this."
In his 2024 campaign, however, President-elect Donald Trump also rejected the deal and <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42295766/u-s-steel-stock-falls-as-trump-pledges-to-block-nippon-steel-acquisition">pledged to thwart it</a> in favor of reviving U.S. Steel <a href="https://www.benzinga.com/24/12/42281749/trump-says-he-will-make-us-steel-great-again-through-tariffs-cautions-nippon-steel-buyer-beware">through tariffs and tax breaks</a>.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

NPSCY

Kevin O'Leary Says Biden Blocking The Sale Of U.S. Steel A 'Mistake,' Claims The Government Is 'Picking Winners And Losers'

UBS analyst Ashwani Verma maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and raises the price target from $415 to $475.

UTHR

UBS Maintains Buy on United Therapeutics, Raises Price Target to $475

Trading Ideas

RVPH

Reviva Pharmaceuticals Option Alert: 1,491 Jul $2.50 Calls Swept Near Ask At $0.451 With 2.5K OI; Stock Trading Around $1.95

Susquehanna analyst Bascome Majors maintains Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) with a Positive and lowers the price target from $92 to $90.

Susquehanna Maintains Positive on Canadian Pacific Kansas, Lowers Price Target to $90

UBS analyst Colin Bristow maintains Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Neutral and lowers the price target from $31 to $29.

UBS Maintains Neutral on Pfizer, Lowers Price Target to $29

UBS analyst Colin Bristow maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Buy and lowers the price target from $125 to $120.

UBS Maintains Buy on Merck & Co, Lowers Price Target to $120

Susquehanna analyst Bascome Majors maintains Canadian National Railway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) with a Neutral and lowers the price target from $125 to $115.

Susquehanna Maintains Neutral on Canadian National Railway, Lowers Price Target to $115

MCVT

Mill City Ventures III Shares Halted On Circuit Breaker To The Downside, Stock Now Down -33.8%

BFRI

Biofrontera Shares Resume Trade

TD Cowen analyst Robert Moskow downgrades WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) from Hold to Sell and lowers the price target from $18 to $16.

Downgrades

TD Cowen Downgrades WK Kellogg to Sell, Lowers Price Target to $16

LAES

SEALSQ Shares Resume Trade Then Again Halted On Circuit Breaker To The Downside, Stock Now Down -53.3%

Biofrontera Shares Halted On Circuit Breaker To The Upside, Stock Now Up 17.1%

UBS analyst John Lovallo maintains Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) with a Buy and lowers the price target from $192 to $185.

UBS Maintains Buy on Toll Brothers, Lowers Price Target to $185

U.S. stocks traded lower this morning, with the Dow Jones index falling around 0.2%% on Wednesday.
Following the market opening Wednesday, the Dow traded down 0.19% to 42,449.51 while the NASDAQ dipped 0.26% to 19,439.95. The S&amp;P 500 also fell, dropping, 0.17% to 5,898.88.
Check This Out: <a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Financial shares jumped by 0.1% on Wednesday.
In trading on Wednesday, health care shares fell by 0.7%.
Top Headline
Acuity Brands, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) reported weaker-than-expected revenue for its fiscal first quarter.
The company posted net sales growth of 1.8% year over year to $951.6 million, missing the analyst consensus estimate of $956.2 million. It clocked an adjusted EPS of $3.97, beating the analyst consensus estimate of $3.89.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sana Biotechnology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares shot up 282% to $6.30 after the company on Tuesday announced clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.</li>
<li>Shares of Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>)got a boost, surging 170% to $2.9500 after the company announced it was awarded a US patent for its PTSD treatment titled &#8216;Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.&#8217;</li>
<li>CURRENC Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares were also up, gaining 146% to $3.42 after the company announced the launch of its AI call center.</li>
</ul>
Equities Trading DOWN
<ul>
<li>DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) shares dropped 64% to $3.2583 after the company announced the pricing of a $5.1 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Shares of Jasper Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) were down 54% to $8.22. The company reported preliminary data from its BEACON Phase 1b/2a study.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) was down, falling 51% to $0.0555. XTI Aerospace priced $20 million offering of 363,636,364 shares of common stock at a price of $0.055 per share.</li>
</ul>
Commodities In commodity news, oil traded up 0.3% to $74.45 while gold traded up 0.7% at $2,683.30.
Silver traded up 1.1% to $31.02 on Wednesday, while copper rose 1% to $4.2360.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 0.6%, Germany's DAX 40 fell 0.3% and France's CAC 40 dipped 1%. Spain's IBEX 35 Index fell 0.6%, while London's FTSE 100 slipped 0.4%.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 falling 0.26%, China's Shanghai Composite Index gaining 0.02%, Hong Kong's Hang Seng Index declining 0.86% and India's BSE Sensex falling 0.07%.
Economics
<ul>
<li>U.S. private businesses added 122,000 workers to their payrolls in December down from 146,000 in November and versus expectations of 140,000.</li>
<li>U.S. initial jobless claims fell by 10,000 to 201,000 in the week ending Jan. 4, recording the lowest level in eleven months and versus market estimates of 218,000.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42873668/jim-cramer-lemonade-is-up-too-much-this-health-care-stock-can-go-lower">Jim Cramer: Lemonade Is &#8216;Up Too Much,&#8217; This Health Care Stock Can Go Lower</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DATS

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

SANA

SILO

XTIA

US Stocks Down; Acuity Brands Posts Weak Revenue

WIIM

Biofrontera shares are trading higher after the company announced the last patient completed the 1 year follow-up of study ALA-BCC-CT013 in December 2024.

<a href="https://www.ft.com/content/fe25ff13-aa55-4090-aae5-8c9f96239fd8" title="https://www.ft.com/content/fe25ff13-aa55-4090-aae5-8c9f96239fd8">https://www.ft.com/content/fe25ff13-aa55-4090-aae5-8c9f96239fd8</a>

Biotech

General

'GSK nears $1B deal for biotech developing drug for rare tumour' - Financial Times

Mizuho initiated coverage of Talkspace (TALK) with an Outperform rating and $5 price target The firm noted that Talkspace has become profitable in ...

Talkspace initiated with an Outperform at Mizuho

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

GE Vernova initiated, Merck upgraded: Wall Street's top analyst calls

Today's top stock picks, from AI leaders to drone innovators, using the 4-pillar strategy.

4-Pillar Strategy In Action: Today's Top Market Movers Revealed

The digital health industry has experienced impressive growth, driven by rising healthcare demands, digitalization, and technological innovations. Amid this, Hims & Hers Health (HIMS), GoodRx Holdings (GDRX), and Talkspace (TALK) are strategically positioned to thrive in the sector, making them attractive investment opportunities. Read on… The digital health industry is booming, driven by technological advancements, rising health awareness, and a growing aging population. This presents a golden opportunity to tap into Hims &amp; Hers Health, Inc. (<a href="https://stocknews.com/stock/HIMS/">HIMS</a>), GoodRx Holdings, Inc. (<a href="https://stocknews.com/stock/GDRX/">GDRX</a>), and Talkspace, Inc. (<a href="https://stocknews.com/stock/TALK/">TALK</a>), which are well-positioned to ride the exciting growth wave of digital health.
As the global geriatric population continues to grow, the need for constant health management has never been more critical. Coupled with an increasing focus on health and wellness, people are increasingly seeking proactive and personalized healthcare. This shift is fueling the adoption of digital health technologies at an unprecedented rate.
Technological advancements are at the heart of this surge. <a href="https://www.techtarget.com/searchhealthit/definition/digital-health-digital-healthcare">Wearable devices</a>, mobile health applications, and telemedicine platforms are transforming healthcare. Artificial intelligence and machine learning, in particular, are revolutionizing healthcare applications, from image analysis and patient monitoring to medical device automation, enhancing clinical workflows and efficiency.
The surge in mobile and smartphone subscriptions is another key factor driving this growth. With <a href="https://www.demandsage.com/smartphone-usage-statistics/">approximately 7.21 billion</a> smartphone users globally, representing around 90% of the world's population, mobile devices are becoming essential tools for accessing digital health solutions. This growing mobile connectivity is crucial for the future of digital health.
Looking forward, as per a report by Fortune Business Insights, the global digital health market is expected to soar from $376.68 billion in 2024 to $1.50 trillion by 2032, exhibiting <a href="https://www.fortunebusinessinsights.com/industry-reports/digital-health-market-100227">a CAGR of 18.9%</a>. The rapid expansion indicates the vast potential and lucrative opportunities within the digital health sector.
So, let us dive deep into the fundamentals of three digital health stocks, starting with #3.
Stock #3: Hims &amp; Hers Health, Inc. (<a href="https://stocknews.com/stock/HIMS/">HIMS</a>)
HIMS connects consumers with licensed healthcare professionals through its telehealth platform. Customers can easily purchase curated prescription and non-prescription health products and services directly through HIMS' websites or mobile apps, ensuring convenience and personalized care.
On November 21, HIMS announced that its customers could now supplement their treatment plans with daily <a href="https://investors.hims.com/news/news-details/2024/Hims--Hers-Expands-Nutrition-Support-to-Fuel-Customers-Weight-Loss-Journeys/default.aspx">meal replacement bars and shakes</a> to support their comprehensive weight loss journeys. These products are designed to enhance HIMS' doctor-approved, individualized weight management plans.
By providing a more holistic approach to weight loss, HIMS can strengthen its position as a comprehensive health solution provider, attracting a wider range of customers.
On September 18, HIMS announced an initiative to offer access to <a href="https://investors.hims.com/news/news-details/2024/Hims--Hers-to-Offer-Access-to-Compounded-GLP-1-Injections-for-as-Low-as-99Month-to-U.S.-Military-Veterans-Teachers-Nurses-and-First-Responders/default.aspx">commonly compounded GLP-1 prescriptions</a> for as low as $99 a month. The offer is available to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. This move will increase HIMS' customer base by tapping into vital and underserved groups.
For the fiscal third quarter that ended September 30, 2024, HIMS' revenue increased 77.1% year-over-year to $401.56 million. Its gross profit grew 69.7% from the year-ago value to $317.89 million. Moreover, the company's <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> rose 311.1% year-over-year to $51.10 million.
Additionally, total comprehensive income and net income per share attributable to common stockholders came in at $75.99 million and $0.32, compared to a net loss and loss per share of $7.44 million and $0.04 in the previous year's quarter, respectively.
Analysts expect HIMS' revenue and EPS for the fiscal fourth quarter ending December 2024 to increase 90.4% and 961.8% year-over-year to $469.48 million and $0.11, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
Shares of HIMS have surged 62.8% over the past six months and 281.6% over the past year, closing the last trading session at $33.92.
HIMS' <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> mirror its fundamentals. HIMS has an A grade for Quality and Growth. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
Within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry, HIMS is ranked #33 out of 63 stocks. In addition to the POWR Rating highlighted above, you can check HIMS' ratings for Stability, Sentiment, Momentum, and Value <a href="https://stocknews.com/stock/HIMS/">here</a>.
Stock #2: GoodRx Holdings, Inc. (<a href="https://stocknews.com/stock/GDRX/">GDRX</a>)
GDRX provides a consumer-focused digital healthcare platform. The company offers a price comparison platform that provides consumers with relevant prescription pricing, and other healthcare products and services, as well as telehealth services through the GoodRx Care platform.
On October 31, GDRX <a href="https://investors.goodrx.com/news-releases/news-release-details/goodrx-unveils-new-e-commerce-platform-launches-opillr">unveiled its new e-commerce platform</a> with Opill&#xAE; as its launch partner. This move could significantly enhance GDRX's competitive edge in the rapidly growing digital health market. By offering a streamlined, user-friendly shopping experience, GDRX strengthens its brand presence and attracts a broader customer base.
Additionally, on October 16, GDRX <a href="https://investors.goodrx.com/news-releases/news-release-details/goodrx-partnering-retail-pharmacies-deliver-pay-over-time-option">announced a partnership</a> with retail pharmacies, including Hy-Vee, a grocery retailer with over 275 retail pharmacies. The collaboration introduces Affirm's "Pay Over Time" option for select medications.
By offering flexible payment plans, GDRX would be able to cater to a wider range of consumers, driving customer loyalty and increasing medication access. Additionally, the expansion into the retail pharmacy sector enables GDRX to tap into a larger market, broadening its reach and solidifying its leadership position in the healthcare space.
For the fiscal 2024 third quarter that ended September 30, GDRX's revenue increased 8.5% year-over-year to $195.25 million. Its adjusted operating income grew 17.6% from the year-ago value to $49.39 million.
Moreover, the company's adjusted net income and adjusted EPS rose 25% and 33.3% from the prior year's quarter to $31.94 million and $0.08, respectively.
Street expects GDRX's revenue and EPS for the fiscal year ending December 2025 to increase 4.1% and 120.5% year-over-year to $825.66 million and $0.16, respectively. In addition, the company topped the consensus revenue estimates in three of the four trailing quarters.
GDRX's shares surged 4.3% over the past five days to close the last trading session at $5.07.
GDRX's solid prospects are projected in its POWR Ratings. The stock has an overall rating of B, translating to a Buy in our proprietary rating system.
GDRX has an A grade for Growth and a B for Value. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, it is ranked #36 out of 156.
<a href="https://stocknews.com/stock/GDRX/">Click here</a> to access GDRX's ratings for Quality, Momentum, Sentiment, and Stability.
Stock #1: Talkspace, Inc. (<a href="https://stocknews.com/stock/TALK/">TALK</a>)
TALK operates a behavioral healthcare company that offers psychotherapy and psychiatry services through its platform to individuals, enterprises, health plans, and employee assistance programs. The company also offers text, audio, and video-based psychotherapy from licensed therapists.
On October 23, TALK <a href="https://investors.talkspace.com/news-releases/news-release-details/talkspace-teams-wisdo-health-tackle-loneliness-amongst-older">announced its strategic partnership</a> with Wisdo Health, an AI-powered platform addressing loneliness and improving mental health for the 65+ community. The collaboration expands TALK's services, enhancing access to mental health resources while reducing healthcare costs.
It could boost member engagement, address the growing senior mental health crisis, and position TALK as a leader in senior health, driving both growth and market expansion.
On September 17, TALK partnered with Amazon Health Services to enhance the <a href="https://investors.talkspace.com/news-releases/news-release-details/talkspace-partners-amazon-health-services-help-millions-discover">visibility of its mental health care services</a> on Amazon.com. The partnership allows millions of U.S. shoppers to easily discover TALK's behavioral health benefits, granting access to over 5,000 licensed therapists and increasing awareness and accessibility for those in need.
By tapping into the company's massive customer base, TALK can ensure more people are aware of its offerings, driving both growth and market penetration.
For the fiscal third quarter that ended September 30, 2024, TALK's total revenue increased 22.6% year-over-year to $47.40 million. Its gross profit grew 14.7% from the year-ago value to $21.62 million. Plus, the company's adjusted EBITDA came in at $2.35 million, compared to a loss of $2.80 million in the previous year's quarter.
Additionally, TALK reported a net income of $1.87 million and net income per share of $0.01, reversing the previous year's quarter's net loss of $4.41 million and loss per share of $0.03.
The consensus revenue and EPS estimates of $232.88 million and $0.06 for the fiscal year ending December 2025 exhibit a year-over-year rise of 23.3% and 833.3%, respectively. Furthermore, the company surpassed the consensus revenue estimates in three of four trailing quarters.
Shares of TALK have surged 39.9% over the past six months and 59.7% over the past year to close the last trading session at $3.61.
TALK's prospects are reflected in its POWR Ratings. The stock has a B grade for Sentiment and Quality.
Within the Medical - Services industry, TALK is ranked #30 out of 63 stocks. <a href="https://stocknews.com/stock/TALK/">Click here</a> to access its Momentum, Value, Growth, and Stability ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
<hr />
HIMS shares rose $0.16 (+0.47%) in premarket trading Thursday. Year-to-date, HIMS has gained 281.12%, versus a 29.05% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/hims-gdrx-talk-3-digital-health-companies-enhancing-patient-engagement/>3 Digital Health Companies Enhancing Patient Engagement</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Digital Health Companies Enhancing Patient Engagement

Northland Securities analyst Bobby Brooks, CFA maintained a Buy rating on Talkspace (TALK – Research Report) yesterday and set a price target of $5...

Talkspace (TALK) Gets a Buy from Northland Securities

KeyBanc initiated coverage of Talkspace (TALK) with an Overweight rating and $4.50 price target The firm expects sales growth of 20%-25%, driven ma...

Talkspace initiated with an Overweight at KeyBanc

Talkspace: A Growth Story

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Talkspace (TALK – Research Report), Centene (CNC – Research Repor...

Analysts Conflicted on These Healthcare Names: Talkspace (TALK), Centene (CNC) and Alkermes (ALKS)

Talkspace (TALK) is now available to approximately 9.5 million active duty and retired military personnel and their dependents as an in-network ben...

Talkspace now available to 9.5M active duty, retired military, dependents

ALEC

ALGN

ALKS

COHR

DOCS

GDRX

HIMS

HSIC

LFMD

NBIS

NVST

PDCO

PSTG

SNOW

SOLV

TALK

TRMB

VEEV

XRAY

Press Releases

Talkspace Partners With Amazon Health Services to Help Millions Discover Mental Health Benefits

Talkspace Recognized as one of Crain's 2024 Best Places to Work in NYC

Talkspace to Report Third Quarter 2024 and Host Conference Call

Talkspace Teams Up with Wisdo Health to Tackle Loneliness amongst Older Adults 65+

Earnings

Talkspace Announces Third Quarter 2024 Results

Talkspace Launches Campaign for Men's Health Awareness Month Featuring Talkspace Members Opening up About the Importance of Mental Health

Talkspace to Participate in 3rd Annual Needham Virtual Health Tech Conference

Seattle Expands Youth Mental Health Supports with Launch of Talkspace Virtual Therapy

Talkspace to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Health Care

Talkspace Now In-Network Nationally for 9.5 Million Military Personnel and their Families, Making Mental Health Care More Accessible than Ever

Accolade

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Talkspace

Talkspace (TALK) Opzioni

Talkspace (NASDAQ:TALK) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO